Phio Pharmaceuticals Corp

Company Profile

Phio Pharmaceuticals Corp had its IPO on 2012-05-10 under the ticker symbol PHIO.

The company operates in the Healthcare sector and Biotechnology industry. Phio Pharmaceuticals Corp has a staff strength of 9 employees.

Stock update

Shares of Phio Pharmaceuticals Corp opened at $2.22 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.08 - $2.22, and closed at $2.1.

This is a -4.11% slip from the previous day's closing price.

A total volume of 5,946 shares were traded at the close of the day’s session.

In the last one week, shares of Phio Pharmaceuticals Corp have slipped by -1.41%.

Phio Pharmaceuticals Corp's Key Ratios

Phio Pharmaceuticals Corp has a market cap of $4.73 million, indicating a price to book ratio of 0.3842 and a price to sales ratio of 48.0082.

In the last 12-months Phio Pharmaceuticals Corp’s revenue was $0 with a gross profit of $-7012000 and an EBITDA of $-12389000. The EBITDA ratio measures Phio Pharmaceuticals Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Phio Pharmaceuticals Corp’s operating margin was 0% while its return on assets stood at -47.97% with a return of equity of -92.6%.

In Q2, Phio Pharmaceuticals Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Phio Pharmaceuticals Corp’s PE and PEG Ratio

Forward PE

0.2318

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-8.75 per share while it has a forward price to earnings multiple of 0.2318 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Phio Pharmaceuticals Corp’s profitability.

Phio Pharmaceuticals Corp stock is trading at a EV to sales ratio of 172.2001 and a EV to EBITDA ratio of 0.7505. Its price to sales ratio in the trailing 12-months stood at 48.0082.

Phio Pharmaceuticals Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$12.30 million

Total Liabilities

$2.39 million

Operating Cash Flow

$0

Capital Expenditure

$5000

Dividend Payout Ratio

0%

Phio Pharmaceuticals Corp ended 2024 with $12.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.30 million while shareholder equity stood at $9.90 million.

Phio Pharmaceuticals Corp ended 2024 with $0 in deferred long-term liabilities, $2.39 million in other current liabilities, in common stock, $-134531000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.31 million and cash and short-term investments were $11.31 million. The company’s total short-term debt was $104,000 while long-term debt stood at $0.

Phio Pharmaceuticals Corp’s total current assets stands at $12.04 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $641000.00 and inventory worth $0.

In 2024, Phio Pharmaceuticals Corp's operating cash flow was $0 while its capital expenditure stood at $5000.

Comparatively, Phio Pharmaceuticals Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.1

52-Week High

$9.4188

52-Week Low

$2.04

Analyst Target Price

$72

Phio Pharmaceuticals Corp stock is currently trading at $2.1 per share. It touched a 52-week high of $9.4188 and a 52-week low of $9.4188. Analysts tracking the stock have a 12-month average target price of $72.

Its 50-day moving average was $2.51 and 200-day moving average was $4.26 The short ratio stood at 0.64 indicating a short percent outstanding of 0%.

Around 103.2% of the company’s stock are held by insiders while 216.2% are held by institutions.